The pill formulation of zanubrutinib (Brukinsa; BeOne) has become authorized for all 5 indications across numerous hematological cancers.The procedure is administered by way of an individual infusion,five pursuing a conditioning program of higher-dose chemotherapy, and it utilizes a individual’s genetically modified hematopoietic (blood) stem cel